Search Within

Michael John Mauro

  1. "2020"
Formats
  1. Meeting Abstract (17)
  2. Journal Article (6)
  3. Correspondence (1)
  4. Guidelines (1)
  5. Review (1)
Groups
  1. Adult Leukemia (26)
  2. Center for Hematologic Malignancies (26)
  3. Department of Medicine (26)
  4. Hematologic Malignancies, Division of (26)
  5. Breast Medicine Service (1)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (1)

More Groups

People
  1. Ellin Berman (2)
  2. Ahmet Dogan (1)
  3. Allison Sigler (1)
  4. Amber King (1)
  5. Bradley Beattie (1)
  6. Daniel Danila (1)

More People

Years
  1. 2020 (26)
Publications
  1. Blood (10)
  2. Clinical Lymphoma, Myeloma and Leukemia (4)
  3. Leukemia and Lymphoma (3)
  4. Journal of Clinical Oncology (2)
  5. Arteriosclerosis Thrombosis and Vascular Biology (1)
  6. European Journal of Heart Failure (1)

More Publications

Publishers
  1. American Society of Hematology (10)
  2. Elsevier Inc. (4)
  3. Taylor & Francis Group (3)
  4. American Society of Clinical Oncology (2)
  5. Elsevier Science, Inc. (1)
  6. Lippincott Williams & Wilkins (1)

More Publishers

Results (26)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Myeloid neoplasm with eosinophilia/basophilia and ETV6-ABL1 rearrangements: Cell of origin and response to tyrosine kinase inhibition
    Meeting Abstract

    Yao, J.; Xu, L.; Aypar, U.; Londono, D.; Gao, Q.; Baik, J.; Dietz, J.; Benayed, R.; Sigler, A.; Yabe, M.; more...
    Journal of Molecular Diagnostics (2020)

    Fulltext@MSK | Save
  • Cardiovascular mortality among chronic myeloid leukemia patients in the pre-tyrosine kinase inhibitor (TKI) and TKI eras: A surveillance, epidemiology and end results (SEER) analysis
    Journal Article

    Wang, Q.; Jiang, C.; Zhang, Y.; Zhang, Y.; Yue, B.; Zheng-Lin, B.; Zhao, Y.; Mauro, M. J.
    Leukemia and Lymphoma (2020)

    Fulltext@MSK | Save
  • Asciminib in relapsed chronic myeloid leukemia - The authors reply
    Correspondence

    Mauro, M. J.; Hughes, T. P.
    New England Journal of Medicine (2020)

    Fulltext@MSK | Save
  • Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: The DASFREE study
    Journal Article

    Shah, N. P.; García-Gutiérrez, V.; Jiménez-Velasco, A.; Larson, S.; Saussele, S.; Rea, D.; Mahon, F. X.; Levy, M. Y.; Gómez-Casares, M. T.; Pane, F.; more...
    Leukemia and Lymphoma (2020)

    Fulltext@MSK | Save
  • Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: A dual-center, propensity score-matched analysis
    Journal Article

    Tremblay, D.; King, A.; Li, L.; Moshier, E.; Coltoff, A.; Koshy, A.; Kremyanskaya, M.; Hoffman, R.; Mauro, M. J.; Rampal, R. K.; more...
    Leukemia and Lymphoma (2020)

    Fulltext@MSK | Save
  • Tyrosine kinase inhibitors in leukemia and cardiovascular events: From mechanism to patient care
    Review

    Manouchehri, A.; Kanu, E.; Mauro, M. J.; Aday, A. W.; Lindner, J. R.; Moslehi, J.
    Arteriosclerosis Thrombosis and Vascular Biology (2020)

    Fulltext@MSK | Save